Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452865 | 1.00 | KDM1A (0.44) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29364160 | 0.89 | SMN1; SMN2 (0.47) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8326625 | 0.89 | SMN1; SMN2 (0.47) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL18860228 | 0.89 | SMN1; SMN2 (0.47) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL25046303 | 0.83 | KDM1A (0.44) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29467496 | 0.83 | KDM1A (0.44) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29455941 | 0.83 | KDM1A (0.44) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6947042 | 0.83 | PDE4B (0.44) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29467502 | 0.82 | KDM1A (0.51) | KDM1AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20337417 | 0.81 | BTK (0.34) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| CN-114206885-B | Pyrazolo [3,4-B ] pyrazines SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2025-05-02 | — | — | CN | disclosed |
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4017855-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| CN-114206885-A | Pyrazolo [3,4-B ] pyrazine SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| CN-112625028-A | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107922388-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107787323-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | KDM1A 574/4885HTT 1275/4885SMN1; SMN2 3724/4885 |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | PTPN5, PTPRZ1, PTPN1 | KDM1A 898/4885HTT 1403/4885SMN1; SMN2 3093/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | KDM1A 284/4885HTT 2538/4885SMN1; SMN2 2037/4885 |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPRZ1, PTPN1 | KDM1A 898/4885HTT 1403/4885SMN1; SMN2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.